Search

Your search keyword '"Kjeldsen, SE"' showing total 871 results
Start Over Author "Kjeldsen, SE"
871 results on '"Kjeldsen, SE"'

3. AVERAGE ACHIEVED BP <130/80 MMHG IN HIGH-RISK MIDDLE-AGED AND OLDER HYPERTENSIVE PATIENTS PROVIDES STRONG CARDIOVASCULAR PROTECTION EXCEPT IN LEFT VENTRICULAR HYPERTROPHY

Author

Heimark, S, Mehlum, M, Mancia, G, Soraas, C, Liestöl, K, Kjeldsen, S, Larstorp, A, Rostrup, M, Mariampillai, J, Wachtell, K, Julius, S, Weber, M, Mehlum, MH, Soraas, CL, Kjeldsen, SE, Larstorp, ACK, Mariampillai, JE, Weber, MA, Heimark, S, Mehlum, M, Mancia, G, Soraas, C, Liestöl, K, Kjeldsen, S, Larstorp, A, Rostrup, M, Mariampillai, J, Wachtell, K, Julius, S, Weber, M, Mehlum, MH, Soraas, CL, Kjeldsen, SE, Larstorp, ACK, Mariampillai, JE, and Weber, MA

Published
2023

7. Late outcomes of renal denervation are more favourable than early ones: facts or fancies?

Author

Persu, A, Stoenoiu, M, Maes, F, Kreutz, R, Mancia, G, Kjeldsen, S, Stoenoiu, MS, Kjeldsen, SE, Persu, A, Stoenoiu, M, Maes, F, Kreutz, R, Mancia, G, Kjeldsen, S, Stoenoiu, MS, and Kjeldsen, SE

Abstract

Following second-generation randomized trials, there is evidence that renal denervation (RDN) decreases blood pressure (BP), although to a lesser extent than suggested in the initial controlled and observational studies. The recent publication of the 36-month follow-up of the Symplicity HTN-3 trial has raised expectations, suggesting increasing, late benefits of the procedure, despite initially negative results. These findings come after those obtained at 36 months in the sham-controlled trial SPYRAL HTN-ON MED and in the Global Symplicity Registry. However, they are susceptible to biases inherent in observational studies (after unblinding for sham-control) and non-random, substantial attrition of treatment groups at 36 months, and used interpolation of missing BPs. More importantly, in SPYRAL HTN-ON MED and Symplicity HTN-3, long-term BP changes in patients from the initial RDN group were compared with those in a heterogeneous control group, including both control patients who did not benefit from RDN and patients who eventually crossed over to RDN. In crossover patients, the last BP before RDN was imputed to subsequent follow-up. In Symplicity HTN-3, this particular approach led to the claim of increasing long-term benefits of RDN. However, comparison of BP changes in patients from the RDN group and control patients who did not undergo RDN, without imputation of BPs from crossover patients, does not support this view. The good news is that despite the suggestion of sympathetic nerve regrowth after RDN in some animal models, there is no strong signal in favour of a decreasing effect of RDN over time, up to 24 or even 36 months. Still, current data do not support a long-term increase in the effect of RDN and the durability of RDN-related BP reduction remains to be formally demonstrated.

Published
2023

8. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

Author

Esler, M, Kjeldsen, S, Pathak, A, Grassi, G, Kreutz, R, Mancia, G, Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G, Esler, M, Kjeldsen, S, Pathak, A, Grassi, G, Kreutz, R, Mancia, G, Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, and Mancia G

Abstract

Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials. Hypertension is characterised by activation of the sympathetic nervous system from early to late phases, which makes beta-blockers an appropriate treatment seen from a pathophysiological viewpoint, especially in patients with an elevated heart rate. Beta-blockers represent a heterogenous class of drugs with regard to both pharmacodynamic and pharmacokinetic properties. This position is manifest by reference to another clinical context, beta-blocker treatment of heart failure, where unequivocally there is no class effect (no similar benefit from all beta-blockers); there are good and less good beta-blockers for heart failure. Analogous differences in beta-blocker efficacy is also likely in hypertension. Beta-blockers are widely used for the treatment of diseases comorbid with hypertension, in approximately 50 different concomitant medical conditions that are frequent in patients with hypertension, leading to many de facto beta-blocker first choices in clinical practice. Thus, beta-blockers should be regarded as relevant first choices for hypertension in clinical practice, particularly if characterised by a long half-life, highly selective beta-1 blocking activity and no intrinsic agonist properties.SUMMARYBeta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trialsHypertension is characterised by activation of the sympathetic nervous system from early to late phases, which makes beta-blockers an appropriate treatment seen from a pathophysiological viewpoint, especially in patients with an elevated heart rateBeta-blockers represent a heterogenous class of drug

Published
2022

9. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Author

Adler, A, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, NS, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, RP, Chalmers, J, Cushman, WC, Cutler, J, Davis, BR, Devereaux, RB, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, AK, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, JB, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, CR, Patel, A, Pepine, CJ, Pfeffer, MA, Pitt, B, Poulter, NR, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, WH, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, ZY, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, Wang, J, Adler, A, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, NS, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, RP, Chalmers, J, Cushman, WC, Cutler, J, Davis, BR, Devereaux, RB, Dwyer, J, Estacio, R, Fagard, R, Fox, K, Fukui, T, Gupta, AK, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lewis, JB, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Mancia, G, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Ogihara, T, Ohkubo, T, Palmer, CR, Patel, A, Pepine, CJ, Pfeffer, MA, Pitt, B, Poulter, NR, Rakugi, H, Reboldi, G, Reid, C, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, van Gilst, WH, Verdecchia, P, Wachtell, K, Whelton, P, Wing, L, Woodward, M, Yui, Y, Yusuf, S, Zanchetti, A, Zhang, ZY, Anderson, C, Baigent, C, Brenner, BM, Collins, R, de Zeeuw, D, Lubsen, J, Malacco, E, Neal, B, Perkovic, V, Rodgers, A, Rothwell, P, Salimi-Khorshidi, G, Sundström, J, Turnbull, F, Viberti, G, and Wang, J

Abstract

Background: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure. Methods: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat. Findings: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 m

Published
2021

10. InMemoriam: Jiri Widimsky Sr. 1925-2020

Author

Kreutz, R, Cífková, R, Kjeldsen, S, Narkiewicz, K, Burnier, M, Oparil, S, Mancia, G, Kjeldsen, SE, Kreutz, R, Cífková, R, Kjeldsen, S, Narkiewicz, K, Burnier, M, Oparil, S, Mancia, G, and Kjeldsen, SE

Published
2021

11. In memoriam: Jiri Widimsky Sr. 1925-2020

Author

Kreutz, R, Cífkova, R, Kjeldsen, S, Narkiewicz, K, Burnier, M, Oparil, S, Mancia, G, Kjeldsen, SE, Kreutz, R, Cífkova, R, Kjeldsen, S, Narkiewicz, K, Burnier, M, Oparil, S, Mancia, G, and Kjeldsen, SE

Published
2021

12. In memoriam: Peter Sleight 1929-2020

Author

Kreutz, R, Kjeldsen, S, Burnier, M, Narkiewicz, K, Oparil, S, Mancia, G, Kjeldsen, SE, Kreutz, R, Kjeldsen, S, Burnier, M, Narkiewicz, K, Oparil, S, Mancia, G, and Kjeldsen, SE

Published
2020

14. Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension

Author

Williams, B, Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, de Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, Rosei, EA, Clement, DL, Kjeldsen, SE, Lip, GYH, McManus, R, Schmieder, RE, Williams, B, Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, de Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, Rosei, EA, Clement, DL, Kjeldsen, SE, Lip, GYH, McManus, R, and Schmieder, RE

Published
2019

15. 2018 ESC/ESH Guidelines for the management of arterial hypertension

Author

Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, de Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchettit, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, Rosei, EA, Clement, DL, Kjeldsen, SE, Lip, GYH, McManus, R, Schmieder, RE, Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, de Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchettit, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, Rosei, EA, Clement, DL, Kjeldsen, SE, Lip, GYH, McManus, R, and Schmieder, RE

Published
2019

16. Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: Subgroup analysis of the DISTINCT randomised trial

Author

Mancia, G, Cha, G, Gil-Extremera, B, Harvey, P, Lewin, AJ, Villa, G, Kjeldsen, SE, Agaiby, J, Aggarwal, N, Ainsworth, P, Akhras, R, Amaluan, V, Ballarin, A, Bardauskiene, L, Berra, FC, Blagden, M, Bodalia, B, Borghi, C, Bundy, C, Burgess, L, Buynak, R, Cafferata, A, Cahill, T, Capiau, L, Capuano, V, Casanova, R, Cecil, J, Chapman, J, Chilvers, M, Christensen, S, Cho, Y-H, Chung, W-B, Cipollone, F, Coca, A, Colombo, H, Contreras, EM, Crowley, D, Cusco-Prieto, B, Decarlini, F, Doh, J-H, Dzongowski, P, Dzyak, G, Ellery, A, Extremera, BG, Farias, E, Farrington, C, Fidelholtz, J, Fouche, L, Gabito, A, Gainza, M, Gani, M, Gaunt, R, Gelersztein, E, Giuliano, M, Glazunov, A, Glorioso, N, Goloschekin, B, Gumbley, M, Gupta, A, Guzman, L, Ha, J-W, Hart, R, Haworth, D, Henein, S, Henry, D, Her, S-H, Heyvaert, F, Hollanders, G, Hominal, M, Hong, B-K, Hong, T-J, Hwang, K-K, Jacovides, A, Jacqmein, J, Jeon, HK, Jones, N, Kanani, S, Kang, H, Karpenko, O, Kenton, D, Kimzey, N, Kovalenko, V, Kushnir, M, Lasko, B, Lee, KJ, Lee, N, Lewin, A, Litvak, M, Luksiene, D, Majul, C, Mannarino, E, Manuale, O, Marcadis, A, Miller, D, Mills, R, Misik, K, Mortelmans, J, O'Mahony, M, O'Mahony, W, Park, C, Pedrinelli, R, Petrulioniene, Z, Pettyjohn, F, Piskorz, D, Poss, G, Pudi, K, Pyun, WB, Raad, G, Raila, G, Ramirez Espinosa, MF, Ramlachan, P, Rhee, M, Rudenko, L, Ruiz, TS, Ryan, J, Schacter, G, Shin, J-H, Short, D, Sica, D, Sirenko, Y, Slapikas, R, Somani, R, Stanislavchuk, M, Stewart, R, Svishchenko, Y, Sychov, O, Teitelbaum, I, Tseluyko, V, Van Rensburg, DJ, Vaquer Perez, JV, Via, LM, Vico, M, Vizir, V, Vogel, D, Wellmann, H, Yoo, BS, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Mancia, G, Cha, G, Gil-Extremera, B, Harvey, P, Lewin, A, Villa, G, Kjeldsen, S, Agaiby, J, Aggarwal, N, Ainsworth, P, Akhras, R, Amaluan, V, Ballarin, A, Bardauskiene, L, Berra, F, Blagden, M, Bodalia, B, Borghi, C, Bundy, C, Burgess, L, Buynak, R, Cafferata, A, Cahill, T, Capiau, L, Capuano, V, Casanova, R, Cecil, J, Chapman, J, Chilvers, M, Christensen, S, Cho, Y, Chung, W, Cipollone, F, Coca, A, Colombo, H, Contreras, E, Crowley, D, Cusco-Prieto, B, Decarlini, F, Doh, J, Dzongowski, P, Dzyak, G, Ellery, A, Extremera, B, Farias, E, Farrington, C, Fidelholtz, J, Fouche, L, Gabito, A, Gainza, M, Gani, M, Gaunt, R, Gelersztein, E, Giuliano, M, Glazunov, A, Glorioso, N, Goloschekin, B, Gumbley, M, Gupta, A, Guzman, L, Ha, J, Hart, R, Haworth, D, Henein, S, Henry, D, Her, S, Heyvaert, F, Hollanders, G, Hominal, M, Hong, B, Hong, T, Hwang, K, Jacovides, A, Jacqmein, J, Jeon, H, Jones, N, Kanani, S, Kang, H, Karpenko, O, Kenton, D, Kimzey, N, Kovalenko, V, Kushnir, M, Lasko, B, Lee, K, Lee, N, Litvak, M, Luksiene, D, Majul, C, Mannarino, E, Manuale, O, Marcadis, A, Miller, D, Mills, R, Misik, K, Mortelmans, J, O'Mahony, M, O'Mahony, W, Park, C, Pedrinelli, R, Petrulioniene, Z, Pettyjohn, F, Piskorz, D, Poss, G, Pudi, K, Pyun, W, Raad, G, Raila, G, Ramirez Espinosa, M, Ramlachan, P, Rhee, M, Rudenko, L, Ruiz, T, Ryan, J, Schacter, G, Shin, J, Short, D, Sica, D, Sirenko, Y, Slapikas, R, Somani, R, Stanislavchuk, M, Stewart, R, Svishchenko, Y, Sychov, O, Teitelbaum, I, Tseluyko, V, Van Rensburg, D, Vaquer Perez, J, Via, L, Vico, M, Vizir, V, Vogel, D, Wellmann, H, Yoo, B, Mancia, G., Cha, G., Gil-Extremera, B., Harvey, P., Lewin, A.J., Villa, G., Kjeldsen, S.E., Agaiby, J., Aggarwal, N., Ainsworth, P., Akhras, R., Amaluan, V., Ballarin, A., Bardauskiene, L., Berra, F.C., Blagden, M., Bodalia, B., Borghi, C., Bundy, C., Burgess, L., Buynak, R., Cafferata, A., Cahill, T., Capiau, L., Capuano, V., Casanova, R., Cecil, J., Chapman, J., Chilvers, M., Christensen, S., Cho, Y.-H., Chung, W.-B., Cipollone, F., Coca, A., Colombo, H., Contreras, E.M., Crowley, D., Cusco-Prieto, B., Decarlini, F., Doh, J.-H., Dzongowski, P., Dzyak, G., Ellery, A., Extremera, B.G., Farias, E., Farrington, C., Fidelholtz, J., Fouche, L., Gabito, A., Gainza, M., Gani, M., Gaunt, R., Gelersztein, E., Giuliano, M., Glazunov, A., Glorioso, N., Goloschekin, B., Gumbley, M., Gupta, A., Guzman, L., Ha, J.-W., Hart, R., Haworth, D., Henein, S., Henry, D., Her, S.-H., Heyvaert, F., Hollanders, G., Hominal, M., Hong, B.-K., Hong, T.-J., Hwang, K.-K., Jacovides, A., Jacqmein, J., Jeon, H.K., Jones, N., Kanani, S., Kang, H., Karpenko, O., Kenton, D., Kimzey, N., Kovalenko, V., Kushnir, M., Lasko, B., Lee, K.J., Lee, N., Lewin, A., Litvak, M., Luksiene, D., Majul, C., Mannarino, E., Manuale, O., Marcadis, A., Miller, D., Mills, R., Misik, K., Mortelmans, J., O'Mahony, M., O'Mahony, W., Park, C., Pedrinelli, R., Petrulioniene, Z., Pettyjohn, F., Piskorz, D., Poss, G., Pudi, K., Pyun, W.B., Raad, G., Raila, G., Ramirez Espinosa, M.F., Ramlachan, P., Rhee, M., Rudenko, L., Ruiz, T.S., Ryan, J., Schacter, G., Shin, J.-H., Short, D., Sica, D., Sirenko, Y., Slapikas, R., Somani, R., Stanislavchuk, M., Stewart, R., Svishchenko, Y., Sychov, O., Teitelbaum, I., Tseluyko, V., Van Rensburg, D.J., Vaquer Perez, J.V., Via, L.M., Vico, M., Vizir, V., Vogel, D., Wellmann, H., Yoo, B.S., DISTINCT Investigators, and [Mancia,G] Unit and Department of Clinical Medicine, University of Milano-Bicocca, IRCCS Istituto Auxologico Italiano, Milan, Italy. [Cha,G] KRK Medical Research Institute, Dallas, TX, USA. [Gil-Extremera,B] Hospital Universitario San Cecilio, Granada, Spain. [Harvey,P] Formerly in The Crouch Oak Family Practice, Addlestone, UK. [Lewin,AJ] National Research Institute, Los Angeles, CA, USA. [Villa,G] Fondazione Salvatore Maugeri—IRCCS, Pavia, Italy. [Kjeldsen,SE] Oslo University Hospital Ullevaal, University of Oslo, Oslo, Norway.

Subjects
Male, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines::Dihydropyridines::Nifedipine [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], Tetrazoles, Blood Pressure, DISTINCT study, Índice de masa corporal, 030204 cardiovascular system & hematology, Benzimidazole, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Bencimidazoles, 0302 clinical medicine, Randomized controlled trial, law, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Urinary Tract Physiological Phenomena::Glomerular Filtration Rate [Medical Subject Headings], Medicine, Tasa de filtración glomerular, 030212 general & internal medicine, Hipercolesterolemia, Tetrazole, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Benzimidazoles [Medical Subject Headings], Middle Aged, Calcium Channel Blockers, Presión sanguínea, Humanos, Antihypertensive Agent, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Biphenyl Compounds [Medical Subject Headings], Hypertension, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings], Compuestos de bifenilo, Diabetes mellitus Tipo 2, Nifedipino, Original Article, Drug Therapy, Combination, Female, Calcium Channel Blocker, Factores de riesgo, medicine.drug, Human, medicine.medical_specialty, Combination therapy, Nifedipine, Subgroup analysis, Placebo, Nifedipine GITS, Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings], 03 medical and health sciences, candesartan, high blood pressure, Internal medicine, Hipertensión, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure [Medical Subject Headings], Internal Medicine, Humans, Antihypertensive Agents, business.industry, Biphenyl Compounds, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemias::Hyperlipidemias::Hypercholesterolemia [Medical Subject Headings], Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Tetrazoles [Medical Subject Headings], Candesartan, Endocrinology, Blood pressure, Benzimidazoles, business, Body mass index
Abstract

none 140 si The DISTINCT study (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) investigated the efficacy and safety of nifedipine GITS/candesartan cilexetil combinations vs respective monotherapies and placebo in patients with hypertension. This descriptive sub-analysis examined blood pressure (BP)-lowering effects in high-risk participants, including those with renal impairment (estimated glomerular filtration rate

Published
2017

17. No Longer a Sine Qua Non for Guideline Authors?

Author

Messerli, FH, Hofstetter, L, Agabiti-Rosei, E, Burnier, M, Elliott, WJ, Franklin, SS, Grodzicki, T, Kario, K, Kjeldsen, SE, Kostis, JB, Laurent, S, Leenen, FH, Lund-Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, SF, Ruilope, LM, Schiffrin, EL, Schmieder, RE, Schwartz, AB, Sever, P, Sowers, JR, Staessen, JA, Wang, J, Weber, M, and Williams, B

Subjects
OLDER, Science & Technology, HYPERTENSION, 1103 Clinical Sciences, AGED 60 YEARS, 1102 Cardiovascular Medicine And Haematology, Peripheral Vascular Disease, Cardiovascular System & Hematology, Cardiovascular System & Cardiology, BLOOD-PRESSURE TARGETS, INHIBITORS, Life Sciences & Biomedicine, METAANALYSIS, ANGIO-EDEMA
Published
2017

18. Who is an expert? Reply

Author

Messerli, FH, Hofstetter, L, Agabiti-Rosei, E, Burnier, M, Elliott, WJ, Franklin, SS, Grodzicki, T, Kario, K, Kjeldsen, SE, Kostis, JB, Laurent, S, Leenen, FH, De Leeuw, PW, Lund-Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, SF, Ruilope, LM, Schiffrin, EL, Schmieder, RE, Schwartz, AB, Sever, P, Sowers, JR, Staessen, JA, Wang, J, Weber, M, Williams, B, MUMC+: MA Alg Interne Geneeskunde (9), and RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience

Subjects
OLDER, Science & Technology, Peripheral Vascular Disease, Cardiovascular System & Hematology, HYPERTENSION, Cardiovascular System & Cardiology, 1103 Clinical Sciences, GUIDELINES, Life Sciences & Biomedicine, 1102 Cardiovascular Medicine And Haematology
Abstract

ispartof: Journal of Hypertension vol:35 issue:11 pages:2327-2328 ispartof: location:Netherlands status: published

Published
2017

19. Reply

Author

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, de Leeuw PW, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, and Williams B

Published
2017

20. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)

Author

Rahimi, K, Canoy, D, Nazarzadeh, M, Salimi-Khorshidi, G, Woodward, M, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Agodoa, L, Algra, A, Asselbergs, FW, Beckett, N, Berge, E, Black, H, Brouwers, FPJ, Brown, M, Bulpitt, CJ, Byington, B, Cutler, J, Devereaux, RB, Dwyer, D, Fagard, R, Fox, K, Fukui, T, Gupta, AJ, Holman, RR, Imai, Y, Ishii, M, Julius, S, Kanno, Y, Kjeldsen, SE, Kostis, J, Kuramoto, K, Lanke, J, Lewis, E, Lievre, M, Lindholm, LH, Lueders, S, MacMahon, S, Matsuzaki, M, Mehlum, MH, Nissen, S, Ogawa, H, Othisgihara, T, Ohkubo, T, Palmer, C, Patel, A, Pepine, C, Pfeffer, M, Poulter, NR, Rakugi, H, Remuzzi, G, Ruggenenti, P, Saruta, T, Schrader, J, Schrier, R, Sever, P, Sleight, P, Staessen, JA, Suzuki, H, Thijs, L, Ueshima, K, Umemoto, S, Van Gilst, WH, Verdecchia, P, Wachtell, K, Yui, Y, Yusuf, S, Baigent, C, Collins, R, De Zeeuw, D, Neal, B, Perkovic, V, Rahman, M, Remme, WJ, Rodgers, A, Sundstrom, J, Turnbull, F, Foundation for Circulatory Health, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Staessen, Jan

Subjects
medicine.medical_specialty, Epidemiology, Disease, REGIMENS, 030204 cardiovascular system & hematology, Research Support, Phase (combat), 03 medical and health sciences, Medicine, General & Internal, 0302 clinical medicine, General & Internal Medicine, Diabetes mellitus, Protocol, medicine, Journal Article, Humans, 030212 general & internal medicine, Intensive care medicine, Non-U.S. Gov't, Stroke, Antihypertensive Agents, Randomized Controlled Trials as Topic, RISK, Protocol (science), Medicine(all), Science & Technology, efficacy and safety of bp lowering treatment, HYPERTENSION, business.industry, Research Support, Non-U.S. Gov't, blood pressure, General Medicine, medicine.disease, PROSPECTIVELY-DESIGNED OVERVIEWS, MODEL, Treatment Outcome, MAJOR CARDIOVASCULAR EVENTS, Blood pressure, Patient level data, meta-analyses, Blood pressure lowering, business, Life Sciences & Biomedicine, Blood Pressure Lowering Treatment Trialists’ Collaboration
Abstract

IntroductionPrevious research from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) and others has shown that pharmacological blood pressure (BP)- lowering substantially reduces the risk of major cardiovascular events, including ischaemic heart disease, heart failure and stroke. In this new phase, the aim is to conduct individual patient-level data (IPD) meta-analyses involving eligible BP-lowering randomised controlled trials (RCTs) to address uncertainties relating to efficacy and safety of BP-lowering treatment.Methods and analysisRCTs investigating the effect of pharmacological BP-lowering, with a minimum of 1000 patient-years of follow-up in each trial arm, are eligible. Our systematic review identified 100 potentially eligible trials. We requested their investigators/sponsors to contribute baseline, follow-up and outcomes data. As of June 2018, the collaboration has obtained data from 49 trials (n=315 046 participants), with additional data currently in the process of being transferred from four RCTs (n=34 642 participants). In addition, data harmonisation has commenced. Scientific activities of the collaboration are overseen by the Steering Committee with input from all collaborators. Detailed protocols for individual meta-analyses will be developed and registered on public platforms.Ethics and disseminationEthics approval has been obtained for this new and extended phase of the BPLTTC, the largest collaboration of de-identified IPD from RCTs. It offers an efficient and ethical manner of re-purposing existing data to answer clinically important questions relating to BP treatment as well as methodological questions relating to IPD meta-analyses. Among the immediate impacts will include reliable quantification of effects of treatment modifiers, such as baseline BP, age and prior disease, on both vascular and non-vascular outcomes. Analyses will further assess the impact of BP-lowering on important, but less well understood, outcomes, such as new-onset diabetes and renal disease. Findings will be published in peer-reviewed medical journals on behalf of the collaboration.

Published
2019

23. The Un-Observed Automated Office Blood Pressure Measurement Technique Used in the SPRINT Study Points to a Standard Target Office Systolic Blood Pressure <140 mmHg

Author

Kjeldsen, S, Mancia, G, Kjeldsen, SE, Kjeldsen, S, Mancia, G, and Kjeldsen, SE

Abstract

The SPRINT study investigators used the un-observed automated office blood pressure measurement technique. When their achieved systolic blood pressure is corrected, target systolic blood pressure for most people remains unchanged: <140mmHg for prevention of cardiovascular diseases and death.

Published
2017

26. Systolic visit-to-visit blood pressure variability increases risk of myocardial infarction and congestive heart failure in patients given valsartan or amlodipine in the value trial

Author

Mehlum, MH, Liestøl, K, Julius, S, Kjeldsen, SE, Hua, TA, Rothwell, PM, Mancia, G, Parati, G, Weber, MA, Berge, E, Mehlum, M, Liestl, K, Julius, S, Kjeldsen, S, Hua, T, Rothwell, P, Mancia, G, Parati, G, Weber, M, and Berge, E

Subjects
systolic visit-to-visit
Abstract

OBJECTIVE: High systolic blood pressure variability has been associated with an increased risk of cardiovascular events, and has been shown to be associated with an increased risk of cardiac events in the VALUE trial. In this analysis we aimed to assess if increased visit-to-visit variability in systolic blood pressure increased the risk of myocardial infarction or heart failure in the VALUE trial patient population. DESIGN AND METHOD: The VALUE trial was a randomised-controlled, double-masked investigation of valsartan versus amlodipine in patients 50 years or older with hypertension and high risk of cardiovascular events. Mean follow-up time was 4.2 years. We calculated the standard deviation (SD) of mean systolic blood pressure from visits 6 months onward, excluding patients with less than 3 visits, or patients with stroke or cardiac events during the first 6 months. In the pooled treatment arms, we grouped SD in quintiles and compared the risk of myocardial infarction and congestive heart failure (fatal/non-fatal events) in the highest and the lowest quintile, using a Cox regression model, adjusting for a number of prognostic variables, including randomised treatment and mean systolic blood pressure from 6 months onwards. RESULTS: Of 13.803 patients included, 503 (3.6%) experienced myocardial infarction and 489 (3.5%) experienced congestive heart failure. Compared to patients with the lowest variability, those in the highest quintile had an increased risk of myocardial infarction and congestive heart failure (HR 3.2, 95% CI 2.3-4.3, p

Published
2016

27. Reducing Microalbuminuria—Does It Lower Cardiovascular Risk?

Author

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlo[Combining Diaeresis]f B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, null Nieminen, Omvik P, Oparil S, and Wan Y

Subjects
Nephrology, General Medicine
Published
2005

28. Lowering Albuminuria—Does It Lower the Cardiovascular Risk?

Author

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlo[Combining Diaeresis]f B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, and Wan Y

Subjects
Nephrology, General Medicine
Published
2005

29. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial

Author

Kjeldsen, S, Berge, E, Bangalore, S, Messerli, F, Mancia, G, Holzhauer, B, Hua, T, Zappe, D, Zanchetti, A, Weber, M, Julius, S, Kjeldsen, SE, Messerli, FH, Hua, TA, Weber, MA., Kjeldsen, S, Berge, E, Bangalore, S, Messerli, F, Mancia, G, Holzhauer, B, Hua, T, Zappe, D, Zanchetti, A, Weber, M, Julius, S, Kjeldsen, SE, Messerli, FH, Hua, TA, and Weber, MA.

Abstract

Previous studies have debated the notion that low blood pressure (BP) during treatment, particularly diastolic (DBP), is associated with increased risk of cardiovascular disease. We evaluated the impact of low BP on cardiovascular outcomes in a high-risk population of 15,244 hypertensive patients, almost half of whom had a history of coronary artery disease (CAD). In the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, patients were randomized to valsartan or amlodipine regimens and followed for 4.2 years (mean) with no difference in the primary cardiovascular endpoint. A Cox proportional hazards model was used to evaluate the relationship between average on-treatment BP and clinical outcomes. The relationship between BP and cardiovascular events was adjusted for age, gender and body mass index, and baseline qualifying risk factors and diseases (smoking, high total cholesterol, diabetes mellitus, proteinuria, CAD, previous stroke and left ventricular hypertrophy). DBP ≥ 90 mmHg, compared with < 90 mmHg, was associated with increased incidence of the primary cardiovascular endpoint (all cardiac events); however, DBP < 70 mmHg, compared with ≥ 70 mmHg, was not associated with increased incidence after covariate adjustment (no J-shaped curve). Similar results were observed for death, myocardial infarction (MI), heart failure and stroke, considered separately. Nadir for MI was at DBP of 76 mmHg and for stroke 60 mmHg. The ratio of MI to stroke increased with lower DBP. In CAD patients the MI to stroke ratio was more pronounced than in patients without CAD but there was no significant J-curve in either group. Systolic BP ≥ 150 but not < 130 mmHg, compared with 130-149 mmHg, similarly was associated with increased risk for primary outcome. In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in p

Published
2016

30. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial

Author

Mancia, G, Kjeldsen, S, Zappe, D, Holzhauer, B, Hua, T, Zanchetti, A, Julius, S, Weber, M, Kjeldsen, SE, Zappe, DH, Hua, TA, Weber, MA, Mancia, G, Kjeldsen, S, Zappe, D, Holzhauer, B, Hua, T, Zanchetti, A, Julius, S, Weber, M, Kjeldsen, SE, Zappe, DH, Hua, TA, and Weber, MA

Abstract

Aims Recent hypertension guidelines recommend that also in high cardiovascular (CV) risk, hypertensive patients blood pressure (BP) is lowered to <140/90 mmHg as no evidence is available supporting the lower target of <130/80 mmHg recommended in previous guidelines. Whether this represents the optimal treatment strategy is debated, however. Methods and results The high CV risk hypertensive patients of the Valsartan Antihypertensive Long-term use Evaluation (VALUE) trial were divided into subgroups according to (i) the percentage of on-treatment visits in which BP was reduced to <140/90 or <130/80 mmHg or (ii) the mean systolic or diastolic BP (SBP/DBP) values achieved during the entire treatment period or up to the occurrence of an event. A progressive increase from <25 to ≥75% of the visits in which BP was <140/90 mmHg was accompanied by a significant, progressive marked decrease in the covariate adjusted risk of CV morbidity and mortality, cause specific CV events (myocardial infarction, heart failure, and stroke), and all-cause mortality. Except for a persistent progressive decrease in stroke, no significant trend to a risk decrease occurred for a similar progressive increment of the proportion of visits with BP <130/80 mmHg. Increasing the proportion of visits with a BP <140/90 mmHg (but not <130/80 mmHg) was accompanied by a decreased risk of events also when differences in baseline risk were adjusted using a propensity score. Finally, compared with patients remaining at a mean on-treatment SBP ≥140 or DBP ≥90 mmHg, the risk of all events was markedly reduced when on-treatment mean SBP was lowered to a mean SBP of 130-139 mmHg or a mean DBP of 80-89 mmHg, whereas at on-treatment mean SBP <130 mmHg or DBP <80 mmHg, an additional risk reduction was found for stroke but for any other type of event, the risk of which remained similar or only slightly greater than that seen at the higher BP target. Conclusions In the high CV risk, hypertensives of the VALUE trial re

Published
2016

32. A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90 mmHg

Author

Mariampillai, J, Eskås, P, Heimark, S, Kjeldsen, S, Narkiewicz, K, Mancia, G, Mariampillai, JE, Eskås, PA, Kjeldsen, SE, Mariampillai, J, Eskås, P, Heimark, S, Kjeldsen, S, Narkiewicz, K, Mancia, G, Mariampillai, JE, Eskås, PA, and Kjeldsen, SE

Abstract

Although high blood pressure (BP) is the leading risk factors for cardiovascular (CV) disease, the optimal BP treatment target in order to reduce CV risk is unclear in the aftermath of the SPRINT study. The aim of this review is to assess large, randomized, and controlled trials on BP targets, as well as review selected observational analyses from other large randomized BP trials in order to evaluate the benefit of intense vs. standard BP control. None of the studies, except SPRINT, favored intense BP treatment. Some of the studies suggested favorable effects of lowering treatment target in patients with diabetes or high risk of stroke. In SPRINT, a new BP measurement method was introduced, and the results must be interpreted in light of this. The results of the observational analyses indicated the best preventive effect when achieving early and sustained BP control rather than low targets. In conclusion, today's guidelines' recommended treatment target of <140/90 mmHg seems sufficient for most patients. Early and sustained BP control should be the main focus.

Published
2016

33. Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses

Author

Kjeldsen, S, Cha, G, Villa, G, Mancia, G, Kjeldsen, SE, Kjeldsen, S, Cha, G, Villa, G, Mancia, G, and Kjeldsen, SE

Abstract

DISTINCT was an 8-week, double-blind, randomized study to investigate the antihypertensive efficacy and safety of various nifedipine gastrointestinal treatment system (GITS)/candesartan cilexetil (N/C) dose combinations, vs respective monotherapies or placebo, in patients with diastolic blood pressure (DBP) ≥95 to <110 mm Hg. The current prespecified analysis compared BP reduction in participants with mild vs moderate baseline hypertension (ie, systolic [S]BP <160 mm Hg vs ≥160 mm Hg and DBP <100 mm Hg vs ≥100 mm Hg). A total of 1362 patients were analyzed by descriptive statistics. In all patient subgroups investigated, the NC combinations (ie, N: 20, 30, or 60 mg; C: 4, 8, 16, or 32 mg daily) provided greater SBP and DBP lowering and higher rates of BP control (defined as BP <140/90 mm Hg) than respective monotherapies or placebo, with greatest absolute BP reductions observed in the moderately elevated SBP or DBP subgroups. A trend to dose-response relationship was observed in each subgroup. In each SBP and DBP subgroup, treatment-related vasodilatory events (flushing, headache, or edema) were less frequent for patients receiving NC combination therapy than N monotherapy. These analyses support the use of calcium antagonist and angiotensin receptor blocker combination therapy in patients with both mild and moderate hypertension, for whom effective BP normalization and good drug tolerance would greatly reduce the risk of cardiovascular events.

Published
2016

34. NON-INVASIVE HEMODYNAMIC MONITORING IN UNCONTROLLED HYPERTENSIVE PATIENTS: EFFECT ON ARTERIAL STIFFNESS AND CENTRAL BLOOD PRESSURE: THE BEAUTY STUDY

Author

Boutouyrie, P, Elmula, F, Rebora, P, Talvik, A, Salerno, S, Miszkowska-Nagorna, E, Liuc, X, Comotti, T, Larstorp, A, Rostrup, M, Qwierblewska, E, Valsecchi, M, Kjeldsen, S, Viigimaa, M, Narkiewicz, K, Parati, G, Laurent, S, Kjeldsen, SE, Boutouyrie, P, Elmula, F, Rebora, P, Talvik, A, Salerno, S, Miszkowska-Nagorna, E, Liuc, X, Comotti, T, Larstorp, A, Rostrup, M, Qwierblewska, E, Valsecchi, M, Kjeldsen, S, Viigimaa, M, Narkiewicz, K, Parati, G, Laurent, S, and Kjeldsen, SE

Published
2016

40. effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the lLsartan Intervention For End point reduction in hypertension Study

Author

Olsen MH, Wachtel K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe Pedersen o, Lindholm LH, Lyle PA, Mieminen MS, Omvik P, Oparil S, Wedel H., DE SIMONE, GIOVANNI, Olsen, Mh, Wachtel, K, Beevers, G, Dahlöf, B, DE SIMONE, Giovanni, Devereux, Rb, de Faire, U, Fyhrquist, F, Ibsen, H, Kjeldsen, Se, Lederballe Pedersen, O, Lindholm, Lh, Lyle, Pa, Mieminen, M, Omvik, P, Oparil, S, and Wedel, H.

Published
2009

41. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results

Author

Kjeldsen, Sverre E, Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil Extremera, Blas, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J., Villa, Giuseppe, Mancia, Giuseppe, the DISTINCT investigators: Agaiby, J, Aggarwal, N, Ainsworth, P, Akhras, R, Amaluan, V, Ballarin, A, Bardauskiene, L, Berra, Fc, Blagden, M, Bodalia, B, Borghi, C, Bundy, C, Burgess, L, Buynak, R, Cafferata, A, Cahill, T, Capiau, L, Capuano, V, Casanova, R, Cecil, J, Cha, G, Chapman, J, Chilvers, M, Christensen, S, Cho, Yh, Chung, Wb, Cipollone, F, Coca, A, Colombo, H, Contreras, Em, Crowley, D, Cusco Prieto, B, Decarlini, F, Doh, Jh, Dzongowski, P, Dzyak, G, Ellery, A, Extremera, Bg, Farias, E, Farrington, C, Fidelholtz, J, Fouche, L, Gabito, A, Gainza, M, Gani, M, Gaunt, R, Gelersztein, E, Giuliano, M, Glazunov, A, Glorioso, N, Goloschekin, B, Gumbley, M, Gupta, A, Guzman, L, Ha, Jw, Hart, R, Harvey, P, Haworth, D, Henein, S, Henry, D, Her, Sh, Heyvaert, F, Hollanders, G, Hominal, M, Hong, Bk, Hong, Tj, Hwang, Kk, Jacovides, A, Jacqmein, J, Jeon, Hk, Jones, N, Kanani, S, Kang, H, Karpenko, O, Kenton, D, Kimzey, N, Kjeldsen, Se, Kovalenko, V, Kushnir, M, Lasko, B, Lee, Kj, Lee, N, Lewin, A, Litvak, M, Luksiene, D, Majul, C, Mannarino, E, Manuale, O, Marcadis, A, Miller, D, Mills, R, Misik, K, Mortelmans, J, O'Mahony, M, O'Mahony, W, Park, C, Pedrinelli, Roberto, Petrulioniene, Z, Pettyjohn, F, Piskorz, D, Poss, G, Pudi, K, Pyun, Wb, Raad, G, Raila, G, Ramirez Espinosa MF, Ramlachan, P, Rhee, M, Rudenko, L, Ruiz, Ts, Ryan, J, Schacter, G, Shin, Jh, Short, D, Sica, D, Sirenko, Y, Slapikas, R, Somani, R, Stanislavchuk, M, Stewart, R, Svishchenko, Y, Sychov, O, Teitelbaum, I, Tseluyko, V, Van Rensburg DJ, Vaquer Perez JV, Via, Lm, Vico, M, Villa, G, Vizir, V, Vogel, D, Wellmann, H, Yoo, B. S., Kjeldsen, Sverre E, Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil-Extremera, Bla, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J, Villa, Giuseppe, Mancia, Giuseppe, Borghi, Claudio, Kjeldsen, S, Sica, D, Haller, H, Cha, G, Gil-Extremera, B, Harvey, P, Heyvaert, F, Lewin, A, Villa, G, and Mancia, G

Subjects
Male, Physiology, Ethnic Group, Administration, Oral, Tetrazoles, Blood Pressure, DISTINCT study, Pharmacology, Benzimidazole, law.invention, combination therapy, Randomized controlled trial, candesartan cilexetil, combination therapy, DISTINCT study, essential hypertension, nifedipine GITS, vasodilatory side effects, law, Ethnicity, Tetrazole, Middle Aged, candesartan cilexetil, Biphenyl compound, Antihypertensive Agent, Treatment Outcome, Tolerability, Aged, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Ethnic Groups, Female, Humans, Hypertension, Nifedipine, Cardiology and Cardiovascular Medicine, Internal Medicine, Administration, Combination, Cardiology, Vasodilatory side effect, ORIGINAL PAPERS: Therapeutic aspects, medicine.drug, Human, Oral, medicine.medical_specialty, Side effect, Combination therapy, Drug Therapy, Internal medicine, medicine, vasodilatory side effects, business.industry, essential hypertension, nifedipine GITS, Candesartan, Blood pressure, Biphenyl Compound, business, Drug-Related Side Effects and Adverse Reaction
Abstract

Objectives: DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS – Candesartan Therapy) aimed to determine the dose–response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension. Methods: In this 8-week, multinational, multicentre, randomized, double-blind, placebo-controlled study, adults with mean seated DBP of at least 95 to less than 110 mmHg received combination or monotherapy with nifedipine GITS (N) 20, 30 or 60 mg and candesartan cilexetil (C) 4, 8, 16 or 32 mg, or placebo. The primary endpoint, change in DBP from baseline to Week 8, was analysed using the response surface model (RSM); this analysis was repeated for mean seated SBP. Results: Overall, 1381 participants (mean baseline SBP/DBP: 156.5/99.6 mmHg) were randomized. Both N and C contributed independently to SBP/DBP reductions [P

Published
2014

44. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration

Author

Teo, KK, Sleight, P, Gao, P, Yusuf, S, Connolly, S, Swedberg, K, Pfeffer, MA, Granger, CB, McMurray, JJV, Sjoelie, AK, Massie, BM, Carson, P, Lewis, JB, Wachtell, K, Dahlof, B, Devereux, RB, Kjeldsen, SE, Julius, S, Ibsen, H, Lindholm, LH, Olsen, MH, Okin, PM, Califf, R, Holman, RR, Haffner, SM, Dagenais, G, Probstfield, J, Anderson, C, Diaz, R, Dans, A, Levine, M, Unger, T, Fagard, R, Diener, H-C, Sacco, RL, Zanchetti, A, Cohn, JN, Weber, M, and Collaboration, ARBT

Published
2011

45. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documental

Author

Mancia, Giuseppe, Laurent, S, AGABITI ROSEI, Enrico, Ambrosioni, E, Burnier, M, Caulfield, Mj, Cifkova, R, Clément, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, Se, Kiowski, W, Mallion, Jm, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, Mh, Rahn, Kh, Redon, J, Rodicio, J, Ruilope, L, Schmieder, Re, Struijker Boudier HA, Van Zwieten PA, Viigimaa, M, and Zanchetti, A.

Published
2009

46. Hypertension

Author

Kjeldsen, SE, Alnes, TA, Fagard, RH, MANCIA, GIUSEPPE, Camm, AJ, Luscher, TF, Serruys, PW, Kjeldsen, S, Alnes, T, Fagard, R, and Mancia, G

Subjects
BP monitoring, Systolic and Diastolic BP values, Therapy, Guideline, MED/09 - MEDICINA INTERNA
Published
2009

47. [Practice guidelines 2007 for the treatment of arterial hypertension]

Author

Mancia, Giuseppe, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germanò, G, Grassi, G, Heagerty, Am, Kjeldsen, Se, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, Re, Struijker Boudier HA, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Dalby Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, Jl, Erdine, S, Kiowski, W, AGABITI ROSEI, Enrico, Ambrosioni, E, Lindholm, Lh, Manolis, A, Nilsson, Pm, Redon, J, and Viigimaa, M.

Subjects
Clinical Trials as Topic, Risk Factors, Hypertension, Humans
Published
2007

48. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

Author

Graham, I, Atar, D, Borch Johnsen, K, Boysen, G, Burell, G, Cifkova, R, Dallongeville, J, De Backer, G, Ebrahim, S, Gjelsvik, B, Herrmann Lingen, C, Hoes, A, Humphries, S, Knapton, M, Perk, J, Priori, Sg, Pyorala, K, Reiner, Z, Ruilope, L, Sans Menendez, S, Scholte, Op, Reimer, Ws, Weissberg, P, Wood, D, Yarnell, J, Zamorano, Jl, Walma, E, Fitzgerald, T, Cooney, Mt, Dudina, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Funck Brentano, C, Filippatos, G, Hellemans, I, Kristensen, Sd, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Altiner, A, Bonora, Enzo, Durrington, Pn, Fagard, R, Giampaoli, S, Hemingway, H, Hakansson, J, Kjeldsen, Se, Larsen, L, Mancia, G, Manolis, Aj, Orth Gomer, K, Pedersen, T, Rayner, M, Ryden, L, Sammut, M, Schneiderman, N, Stalenhoef, Af, Tokgözoglu, L, Wiklund, O, and Zampelas

Subjects
cardiovascular disease, CVD, prevention of cardiovascular disease
Published
2007

49. ESH/ESC 2007 Guidelines for the management of arterial hypertension

Author

Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad Europea, Sociedad Europea de Cardiología, Mancia, Giuseppe, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, Am, Kjeldsen, Se, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, Re, Boudier, Ha, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, Sd, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, Jl, Erdine, S, Kiowski, W, AGABITI ROSEI, Enrico, Ambrosion, E, Lindholm, Lh, Manolis, A, Nilsson, Pm, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, Jm, Manolis, Aj, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, and Williams, B.

Published
2007

50. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Mancia, Giuseppe, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, Am, Kjeldsen, Se, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, Re, Boudier, Ha, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, Sd, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, Jl, Erdine, S, Kiowski, W, AGABITI ROSEI, Enrico, Lindholm, Lh, Viigimaa, M, Adamopoulos, S, Ambrosioni, E, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, Jm, Manolis, Aj, Nilsson, Pm, O'Brien, E, Ponikowski, P, Redon, J, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, and Williams, B.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results